glp-1 agonists and sglt2 inhibitors APhA 2025: Receptor vs Show Varied Benefit for Cardiovascular Outcomes in Patients With Diabetes Benefits of treatment with SGLT2i
Description
Buckley STSS, Kirk RK, Knudsen LB
115 These results suggest that GLP-1RA might be beneficial as a therapeutic agent for treating IBD, providing a new strategy to target inflammation and improve clinical outcomes in affected patients
& Rendell, M
& Elased, K
placebo for 26 weeks and demonstrated a greater efficacy in terms of reduction of body weight and waist circumference (WC) in the liraglutide group [54,55,56]
